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Abstract
Current evidence suggests that ghrelin, a stomach derived peptide, exerts its orexigenic action through specific modulation
of Sirtuin1 (SIRT1)/p53 and AMP-activated protein kinase (AMPK) pathways, which ultimately increase the expression of
agouti-related protein (AgRP) and neuropeptide Y (NPY) in the arcuate nucleus of the hypothalamus (ARC). However, there
is a paucity of data about the possible action of ghrelin on alternative metabolic pathways at this level. Here, we
demonstrate that ghrelin elicits a marked upregulation of the hypothalamic mammalian target of rapamycin (mTOR)
signaling pathway. Of note, central inhibition of mTOR signaling with rapamycin decreased ghrelin’s orexigenic action and
normalized the mRNA expression of AgRP and NPY, as well as their key downstream transcription factors, namely cAMP
response-element binding protein (pCREB) and forkhead box O1 (FoxO1, total and phosphorylated). Taken together, these
data indicate that, in addition to previous reported mechanisms, ghrelin also promotes feeding through modulation of
hypothalamic mTOR pathway.
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Introduction
Ghrelin is a peptidergic hormone mainly secreted by the
stomach, the effects of which are exerted through the growth
hormone secretagogue receptor 1a (GHS-R1a) [1]. Central
ghrelin administration directly activates agouti-related peptide/
neuropeptide Y (AgRP/NPY) and inhibits POMC neurons in the
arcuate nucleus of the hypothalamus (ARC) [2–10], which
ultimately stimulates feeding and decreases energy expenditure
[8,11,12].
Recently, the molecular pathways upstream of these ARC-
derived neuropeptides have been identified. Ghrelin activates
hypothalamic Sirtuin1 (Sirt1)/p53 and AMP-activated protein
kinase (AMPK) signaling pathways, leading to inhibition of de novo
lipogenesis and increased fatty acid oxidation, which causes
changes in mitochondrial respiration and increased production of
reactive oxygen species (ROS) [2,4–10] finally leading to
activation of NPY/AgRP neurons. The molecular mechanisms
linking ghrelin with the induction of Agrp and Npy gene expression
have also been recently identified. It was reported that the
hypothalamic homeobox domain transcription factor BSX
regulates ghrelin’s stimulatory effect on Agrp and Npy gene
expression in rats, an effect that involves an interaction with two
other transcription factors: the phosphorylated cAMP response-
element binding protein (pCREB) and forkhead box O1 (FoxO1),
respectively [7,13,14]. However, in spite of this evidence, it is
unclear whether selective modulation of hypothalamic lipid
metabolism is the unique main effector downstream of AMPK
or if alternative pathways might be involved.
Mammalian target of rapamycin (mTOR) is an evolutionarily
conserved serine-threonine kinase that acts as a cellular sensor of
changes in energy balance, growth factors, nutrients and oxygen
[15–19]. mTOR is a component of at least two multi-protein
complexes: mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2) [15,16,19]. mTORC1 phosphorylates and modulates
the activity of the serine/threonine ribosomal protein S6 kinase 1
(S6K1). In turn S6K1 phosphorylates and activates S6, a ribosomal
protein involved in translation [15,16,19]. Recent evidence has
shown that hypothalamic mTOR signaling plays a major role in
modulating energy balance by responding to nutrient availability
and the hormonal milieu [20–28]. Thus, central administration of
hormones (i.e. leptin, thyroid hormone, ciliary neurotrophic factor
(CNTF), bone morphogenetic protein 7 (BMP7)) or metabolites
(i.e. leucine, a-lipoic acid) regulate feeding through modulation of
hypothalamic mTOR [20,22,23,28,29].
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On the basis of this evidence, the aim of our study was to assess
if ghrelin actions on feeding might be mediated by specific
modulation of mTOR signaling in the hypothalamus. We provide
novel evidence that ghrelin promotes feeding by modulating the
hypothalamic mTOR pathway.
Materials and Methods
Animals
All experiments were carried out in accordance with the
guidelines of the Spanish Committee for Experiments on Animals.
All procedures performed were also approved by the University of
Santiago de Compostela Institutional Bioethics Committee, the
Xunta de Galicia (Local Government) and the Ministry of
Economy and Competitiveness with ID PS09/01880. Outbred
male Sprague-Dawley rats (University of Santiago de Compostela
Animal House) weighing between 250–300 g were housed in-
dividually under standard conditions with an artificial 12:12 hrs
light/dark cycle under constant humidity. Animals were allowed
free access to tap water and fed with standard laboratory chow
during the experimental periods, as described below.
Intracerebroventricular Treatments
For the ghrelin acute experiments, male rats received either an
intracerebroventricular (ICV) administration [28,30–35] of vehicle
(5 ml of saline) or ghrelin (5 mg = 1.5 nmol) in a total volume of
5 ml (Bachem, Bubendorf, Switzerland) [4,5,7,8,10,36]. For the
experiments with rapamycin rats received an ICV injection of
vehicle (5 ml of DMSO) or rapamycin (50 mg in a total volume of
5 ml; Sigma; St Louis, MO, USA) [28] 30 minutes prior to ghrelin
administration. We used 8–10 rats per group and the experiments
were repeated at least twice; animals were treated at 09:00 AM
(one hour after the light cycle had commenced), when they were
satiated. Rats were killed by cervical dislocation. The hypothal-
amus and the ARC (for western blotting) were immediately
homogenized on ice to preserve phosphorylated protein levels or
the whole brain (for studies of in situ hybridization) were dissected,
and stored at 280uC until further processing. The hypothalamus
was defined by the posterior margin of the optic chiasm and the
anterior margin of the mammillary bodies (to the depth of
approximately 2 mm) [5,7,28,32,34,35,37]. Dissection of the ARC
was performed by micropunches under the microscope, as
previously shown [28].
Stereotaxic Microinjection of Ghrelin
Rats were placed in a stereotaxic frame (David Kopf Instruments;
Tujunga, CA, USA) under ketamine/xylazine anesthesia. The
ARC was targeted bilaterally using a 25-gauge needle (Hamilton;
Reno, NV, USA) [28]. The injections were directed to the
following stereotaxic coordinates: 22.8 mm anterior-posterior
(one injection was performed in each ARC), 60.3 mm lateral to
bregma and 10.2 mm deep. Ghrelin (Bachem, Bubendorf, Switzerland;
1 mg in 1 mL of saline during 2 hours) or vehicle (1 mL of saline)
were given. Rats were killed by cervical dislocation. The ARC (for
western blotting) was dissected [28], immediately homogenized on
ice to preserve phosphorylated protein levels and stored at 280uC
until further processing.
Western Blotting
Hypothalamic and ARC protein lysates were subjected to SDS-
PAGE, electrotransferred on a PVDF membrane and probed with
the following antibodies: mTOR, pmTOR Ser2448, pS6K1
Thr389, S6, pS6 Ser235/236 (Cell Signalling; Danvers, MA,
USA), CREB, FoxO1, pCREB-Ser129 and pFoxO1-Ser256 (Santa
Cruz; Santa Cruz, CA, USA) and b-actin (Abcam; Cambridge, UK)
as previously described [5,7,8,10,28,32,34,35].
In situ Hybridization
Coronal brain sections (16 mm) were probed with specific
oligonucleotides for AgRP (59-CGA CGC GGA GAA CGA GAC
TCG CGG TTC TGT GGA TCT AGC ACC TCT GCC-39),
and NPY (59-AGA TGA GAT GTG GGG GGA AAC TAG
GAA AAG TCA GGA GAG CAA GTT TCA TT-39) as
previously published [4,5,7,10,28,30,32,34,35].
Statistical Analysis
Data are expressed as mean 6 SEM in relation (%) to vehicle-
treated rats. Statistic significance was determined by t-Student
when two groups were compared or ANOVA and post-hoc two-
tailed Bonferroni test when more than two groups were compared.
P,0.05 was considered significant.
Results
Central Administration of Ghrelin Increased Food Intake
and Activated mTOR Signaling in a Time-dependent
Fashion
ICV administration of ghrelin exerted a marked orexigenic
action, which was evident 2 hours after injection and was
consistent after 6 hours (Figures 1A and 1B). Recent evidence
has linked hypothalamic mTOR signaling to modulation of
feeding [20–28], thus we aimed to investigate the effect of central
ghrelin on this metabolic pathway. Our data showed that ghrelin
induced a marked activation of mTOR signaling, as demonstrated
by increased protein levels of phosphorylated (active) mTOR
(pmTOR) at Ser2448, and its downstream targets, namely pS6K1
at Thr389 and pS6 at Ser235/236 (Figures 2A and 2B). In all
cases, that stimulatory effect was transient (2 hours without
significant effect at 1 and 6 hours) and associated with no changes
in the total amount of mTOR, S6K1 and S6 protein levels
(Figures 2A and 2B).
Central Administration of Ghrelin Activated mTOR
Pathway in the ARC
Next, we aimed to identify the hypothalamic nucleus where
ghrelin exerted its action on the mTOR pathway. Firstly, we
analyzed the mTOR pathway in the ARC of rats ICV treated with
ghrelin. Our data recapitulated the same effect detected when
analyzing the total hypothalamic protein levels, with ICV ghrelin
inducing a marked activation of mTOR signaling in the ARC
(Figures 2C and 2D). Secondly, to add further anatomical
insight to our studies we analyzed mTOR signaling in the ARC of
rats stereotaxically treated with ghrelin in that nucleus. Our data
showed again that mTOR pathway was activated in the ARC
following ghrelin injection (Figures 2E and 2F). These data
demonstrate that ghrelin exerts a marked stimulatory effect on
hypothalamic mTOR pathway and that this effect is, at least
partially, located in the ARC.
Inhibition of Hypothalamic mTOR Reversed the
Orexigenic Effect of Ghrelin
To determine the existence of any mechanistic link between
ghrelin’s orexigenic effect and the activation of mTOR signaling,
we investigated the effects of rapamycin, an inhibitor of mTOR
[28], on ghrelin action. The selected dose of rapamycin [20,28]
induced neither an anorectic effect per se at any evaluated time
(Figure 3A), nor taste aversion, illness or malaise (data not shown)
Ghrelin and Hypothalamic mTOR Signaling
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Figure 1. Effect of central ghrelin administration on food intake. (A) Two-hour interval and (B) cumulative food intake of rats ICV treated
with vehicle or ghrelin for 6 hours. ***P,0.001 vs. vehicle ICV. All data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0046923.g001
Figure 2. Effect of central ghrelin administration on hypothalamic mTOR pathway. (A, C and E) Western blot autoradiographic images
and (B) hypothalamic or (D and F) ARC protein levels of the different proteins of the mTOR pathway in vehicle or ghrelin treated rats. For the ICV
injections and analysis of the total hypothalamic protein extracts (A and B) rats were treated during 1, 2 and 6 hours. For the ICV and stereotaxic
injections in the ARC followed of analysis of the ARC protein extracts (A and B) rats were treated during 2 hours. *P,0.05, **P,0.01, ***P,0.001 vs.
vehicle (ICV or ARC). All data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0046923.g002
Ghrelin and Hypothalamic mTOR Signaling
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[28], but inhibited hypothalamic mTOR signaling, as demon-
strated by significantly reduced levels of pS6 (Figures 3B and
3C). Although this dose of rapamycin was sub-effective when
injected alone, our data showed that ICV injection of rapamycin
decreased the orexigenic effect of ghrelin at all the evaluated time
points (2, 4 and 6 hours) (Figure 4A).
Inhibition of Hypothalamic mTOR Signaling Prevented
the Ghrelin-induced Increase in AgRP and NPY, as well as
their Upstream Transcription Factors
Having shown that the central inhibition of mTOR signaling
decreased ghrelin’s orexigenic action, we investigated the effect of
this treatment on the expression levels of AgRP, NPY and their
transcription factors. Our results showed that administration of
rapamycin prevented the ghrelin-induced increase in pCREB,
FoXO1 and pFoXO1 (Figures 5A and 5B), as well as AgRP and
NPY (Figures 6A and 6B) in rats. These data demonstrate that
ghrelin’s effects on Agrp and Npy gene expression, as well as their
upstream transcription factors are mediated, at least partially, by
a mTOR signaling-dependent mechanism.
Discussion
In this study we first demonstrate that the orexigenic effect of
ghrelin requires an intact hypothalamic mTOR pathway and that
this action elicits increased levels of AgRP and NPY mRNA
expression in the ARC, through modulation of the transcription
factors pCREB, FoXO1 and pFoXO1.
Current evidence has demonstrated that ghrelin’s orexigenic
effect is mediated by the selective modulation of hypothalamic
SIRT1/p53/AMPK and fatty acid metabolism pathways, as well
Figure 3. Effect of central administration of rapamycin on food intake and hypothalamic mTOR signaling. (A) Food intake, (B) Western
blot autoradiographic images and hypothalamic protein levels of S6 and pS6 of rats ICV treated vehicle or rapamycin. ***P,0.001 vs. vehicle ICV. All
data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0046923.g003
Ghrelin and Hypothalamic mTOR Signaling
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as ROS levels, which ultimately increase AgRP and NPY
expression in the ARC [2,4–10]. Although it is clear that the
aforementioned molecular mechanism is a bona fide component of
ghrelin signaling, it is totally unclear whether alternative metabolic
pathways could mediate ghrelin-induced increases to food intake.
At the hypothalamic level, recent evidence supports the concept
that mTOR signaling plays a pivotal role in the networks
regulating energy homeostasis [20–28]. Additionally, it was
reported that ghrelin and mTOR signaling are interacting at
peripheral level during changes in nutritional status [38].
Furthermore, inhibition of the gastric mTOR signaling by
rapamycin stimulated the expression of gastric ghrelin mRNA in
mice, whereas the activation of the gastric mTOR signaling by L-
leucine decreased the expression of gastric ghrelin [38]. All these
evidence have led us to investigate the possible involvement of the
hypothalamic mTOR pathway on ghrelin’s action.
Our data show that central ghrelin administration promotes
a marked increase in the phosphorylated (active) form of mTOR
and its downstream targets, pS6K1 and p6 in the ARC. Therefore,
we hypothesized that increases in AgRP and NPY levels after
ghrelin administration, and subsequent hyperphagia, might be
mediated by specific modulation of hypothalamic mTOR
signaling, a notion also supported by data showing that mTOR
is expressed in AgRP/NPY neurons in the ARC [20,39]. Our
results show that inhibition of mTOR signaling following
rapamycin treatment negates the orexigenic action of ghrelin
Figure 4. Effect of central administration of rapamycin on the orexigenic effect of ghrelin. (A) Food intake of vehicle or ghrelin ICV
treated rats, previously ICV treated with vehicle or rapamycin. **P,0.01, ***P,0.001 vs. vehicle ICV vehicle ICV;##P,0.01 vs. ghrelin ICV vehicle ICV.
All data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0046923.g004
Figure 5. Effect of central rapamycin administration on ghrelin’s action on hypothalamic transcription factors. (A) Western blot
autoradiographic images and (B) hypothalamic protein levels of hypothalamic transcription factors in vehicle or ghrelin ICV treated rats, previously
ICV treated with vehicle or rapamycin. *P,0.05, **P,0.01, ***P,0.001 vs. vehicle ICV vehicle ICV; #P,0.05, ##P,0.01 vs. ghrelin ICV vehicle ICV. All
data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0046923.g005
Ghrelin and Hypothalamic mTOR Signaling
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treatment. Of note, this action is associated with normalization of
AgRP and NPY expression in the ARC, as well as the two key
transcription factors modulating their expression, pCREB and
FoXO1 (both total and phosphorylated forms). Overall, these
results indicate that ghrelin-induced food intake (at 2 hours and
further time) is mediated by hypothalamic mTOR signaling and
that this effect is placed in the ARC. These results are in
agreement with a recent report showing activation of S6 in the
ARC after central treatment with ghrelin or fasting [40], a situation
where circulating levels of total ghrelin are increased [41].
Although a large quantity of data during the last decade have
shown that hypothalamic mTOR signaling plays a major role in the
modulation of energy homeostasis [20–28], questions remain
regarding the final output of hypothalamic mTOR activation.
Initially, it was proposed that activation of mTOR signaling in the
hypothalamus promoted anorexia; in fact it was demonstrated that
short-term central administration of anorectic factors, such as
leucine, leptin, CNTF, a-lipoic acid or BMP7 increase hypotha-
lamic mTOR signaling [20,22,23,26,29,40]. However, long-term
activation of hypothalamic mTOR signaling elicits an orexigenic
response, indicated by the following evidence. Mice lacking tuberous
sclerosis protein 1 (TSC1, also called hamartin, a major upstream
negative regulator of mTOR) in the hypothalamus (TSC1 KO), as
well as mice with specific deletion of TSC1 within POMC neurons
(POMC-TSC1 KO), develop hyperphagia due to activation of
mTOR [25]. Importantly, as evidenced in our ghrelin paradigm,
both phenotypes are totally reversed by rapamycin administration.
In keeping with these data, we have recently reported that thyroid
hormone-induced feeding, both short-term (central administration)
and long-term (hyperthyroidism), is mediated by selective modula-
tion of the mTOR pathway in the ARC, which elicits increased
expression of AgRP and NPY [28]. Succinctly, our data demon-
strate that both thyroid hormone and ghrelin promote feeding via
activation of mTOR signaling in the ARC.
The reasons for these divergent effects may not be related to the
timing (short-term vs. long-term activation), since in our experi-
ments ghrelin was administrated over a short time period (2–6
hours). Alternatively, in our view, as recently proposed [28,40], the
differences may be related to the existence of nucleus-specific or
even neuron-specific responses. In this sense, it has been reported
that leptin activates mTOR signaling in AgRP neurons in the
ARC but, in contrast, decreases mTOR activity in the VMH [40].
Analogously, in a similar way to ghrelin, thyroid hormone
increases mTOR signaling in the ARC (but not in the VMH)
[28]. It therefore seems feasible that the respective activation of the
mTOR pathway by ghrelin and anorectic factors, such as leptin,
may involve different intracellular events or even interactions with
alternative intracellular transduction pathways to mediate orexi-
genic or anorexigenic responses, a hypothesis that will require
further investigation. In any event our data further highlight the
relevance of cellular sensors, notably AMPK and mTOR, in the
neuroendocrine control of energy homeostasis. In this regard, the
data reported here, as well as previous work assessing the role of
AMPK [5,7,42] may indicate that the orexigenic effect of ghrelin
is mediated by acting in two different hypothalamic nuclei. At the
VMH the effect of ghrelin is mediated by AMPK with the
subsequent alterations in lipid metabolism [5,7,42] while at the
ARC is mediated by mTOR. Further work with selective silencing
of the respective two cellular sensors in these neuronal populations
is needed in order to fully prove this hypothesis. Whatever the
case, it is clear that ghrelin’s orexigenic action is a very well
preserved physiological mechanism, as it requires a complex and
redundant molecular pathway in the hypothalamus, to ultimately
increase AgRP and NPY expression (transcription, translation and
secretion), and subsequently promote feeding.
In summary, our study shows that mTOR activation is
a hypothalamic, mainly ARC-located, mechanism mediating
ghrelin’s action on feeding through increased Agrp and Npy gene
expression. Our data also describe activation of hypothalamic
mTOR signaling as a mediator of food intake, of potential
importance for the understanding and treatment of obesity.
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